Back to Publications
Policy & Research Briefing

Humanitarian and Societal Consequences of Economic Sanctions on Iran: Empirical Evidence, Nordic Implications & International Law

This comprehensive research briefing (MRY-PUB-BRIEF-2026-01) synthesizes UN Human Rights Council findings (A/HRC/51/33/Add.1), Human Rights Watch investigations, peer-reviewed medical studies in The Lancet, and econometric household surveys to document how financial overcompliance blocks life-saving oncology, thalassemia, and epilepsy medicines—including the Nordic case of Sweden's Mölnlycke Health Care halting Mepilex wound dressings for Iranian 'Butterfly Children' (EB).

Executive Summary & Key Empirical Findings

Broad-based unilateral economic sanctions and financial blockades have become a primary instrument of foreign policy toward Iran. Although sanctions frameworks routinely include formal paper exemptions (humanitarian carve-outs) for food and medicine, empirical investigations by the United Nations Human Rights Council, Human Rights Watch (HRW), and peer-reviewed medical journals (The Lancet, BMJ Global Health, Globalization and Health) demonstrate that these exemptions systematically fail in practice [1, 2, 3, 4].

When central bank clearing, SWIFT messaging, maritime insurance, and international supply chains are severed under the threat of secondary sanctions, global banks and European medical manufacturers engage in extreme risk avoidance (de-risking) and overcompliance. Consequently, the direct human cost falls upon ordinary civilians: children suffering from cancer, thalassemia, hemophilia, drug-resistant epilepsy, and rare genetic disorders, alongside the urban middle class that sustains Iran's independent civil society [1, 2, 9].

| Indicator / Patient Group | Documented Empirical Metric | Primary Source |

| :--- | :--- | :--- |

| Share of Imported Medicines by Value | Imported finished drugs represent 3% of Iran's pharmaceutical market by volume, but ~30% of total market value (concentrated in oncology, biologics, and rare diseases). | Human Rights Watch (2019); Eurostat [2] |

| Domestic Production API Dependency | Approximately 33% (one-third) of domestically manufactured medicines in Iran rely on imported Active Pharmaceutical Ingredients (APIs). | Human Rights Watch (2019) [2] |

| WHO Essential Medicines Shortages | Critical supply shortages documented across 73 essential medicines on the WHO Model List of Essential Medicines. | Setayesh & Mackey, Globalization and Health (2016) [4] |

| Contraction in EU Medical Exports | EU exports to Iran fell by $40M in medicines (to $807M) and $40M in medical supplies (to $150M) already in 2018 upon the re-imposition of sanctions. | Human Rights Watch (2019) / Eurostat [2] |

| Epidermolysis Bullosa (EB, "Butterfly Children") | Swedish manufacturer Mölnlycke Health Care halted shipments of Mepilex wound dressings in March 2019 for >800 EB patients due to secondary sanctions compliance risks. | UN Special Rapporteur `A/HRC/51/33/Add.1` (2022); HRW (2019) [1, 2, 3] |

| Thalassemia & Congenital Blood Disorders | Approximately 23,000 thalassemia patients face disrupted supplies of iron-chelating drugs (Desferal / deferoxamine), causing organ damage and preventable mortality. | UN OHCHR (2021–2022); `A/HRC/51/33/Add.1` [1, 3] |

| Household Welfare & Middle-Class Erosion | Currency shocks and chronic inflation severely compressed real wages, pushing urban, female-headed, elderly, and uninsured households below the poverty line. | Salehi-Isfahani (2023); Batmanghelidj (2022) [9, 10] |


1. The Architecture of Humanitarian Failure: Financial Overcompliance & Medical Supply Chains

A widespread assumption in European foreign policy debates is that economic sanctions do not harm civilian healthcare because food and medicine are formally exempt. Both the UN Human Rights Council Report `A/HRC/51/33/Add.1` (2022) and Human Rights Watch's 47-page investigation "Maximum Pressure": US Economic Sanctions Harm Iranians' Right to Health (2019) refute this assumption across three structural dimensions [1, 2]:

  1. Paralysis of International Financial Channels: Following the May 2018 U.S. withdrawal from the JCPOA and the designation of Iran's Central Bank and major financial institutions under secondary sanctions, routine cross-border banking collapsed. International banks routinely refuse to process even licensed humanitarian transactions out of fear of multi-billion-dollar U.S. Treasury fines and exclusion from U.S. dollar clearing [1, 2].
  2. Structural Dependency on High-Value Biologics and APIs: While Iranian domestic manufacturers produce roughly 97 percent of routine pharmaceutical units by volume, imported finished medicines account for approximately 30 percent of the total pharmaceutical market by value [2]. This 30 percent encompasses advanced chemotherapy agents, recombinant clotting factors, monoclonal antibodies, and orphan drugs for rare diseases. Furthermore, one-third (33%) of locally manufactured medications depend on imported Active Pharmaceutical Ingredients (APIs) and chemical reagents that require international trade finance [2, 6].
  3. Failure of Ad-Hoc Humanitarian Channels: The European Union's INSTEX special-purpose vehicle (established in 2019) processed only a single token transaction before being liquidated, while the Swiss Humanitarian Trade Arrangement (SHTA) has remained too narrow and compliance-burdened to meet the medical supply needs of a population of 90 million [1, 2].

2. The Nordic Case Study: Mölnlycke Health Care (Sweden) & Iran's "Butterfly Children" (Epidermolysis Bullosa)

For Finnish and Nordic policymakers, the clearest illustration of how extraterritorial secondary sanctions and corporate overcompliance harm vulnerable civilians involves a flagship Nordic healthcare manufacturer:

> "Of particular concern are significant challenges faced in the procurement and delivery of life-saving medicines and medical equipment, produced by foreign companies and destined for the treatment of rare diseases, including certain types of cancer, thalassemia, haemophilia, leukaemia, ichthyosis, multiple sclerosis, epidermolysis bullosa, autism and certain forms of diabetes."

> — UN Special Rapporteur Alena Douhan, UN Human Rights Council Report `A/HRC/51/33/Add.1`, para. 28 (2022) [1]

  • The Clinical Condition: Epidermolysis Bullosa (EB) is a rare, genetic, and intensely painful connective-tissue disorder affecting more than 800 patients in Iran—predominantly children known as "Butterfly Children" because their skin blisters and tears at the slightest friction [2, 3].
  • The Nordic Connection (*Mepilex*): Standard medical gauze adheres to open EB wounds, tearing off fragile skin layers upon removal. To prevent lethal infections and the fusion of fingers and toes (pseudosyndactyly), EB patients rely on Mepilex, a specialized non-adherent soft silicone foam dressing manufactured by Mölnlycke Health Care (headquartered in Gothenburg, Sweden) [2, 3].
  • Supply Cutoff in March 2019: Prior to the re-imposition of sanctions, the Iranian NGO EB Home distributed Mepilex dressings free of charge to hundreds of afflicted children. In March 2019, Mölnlycke Health Care sent a written communication to EB Home stating that due to U.S. economic sanctions and banking compliance restrictions, it could no longer supply Mepilex to Iran [2, 3].
  • Documented Humanitarian Harm: Deprived of protective dressings, Iranian EB children suffered severe bacterial infections, sepsis, scarring contractures, limb amputations, and multiple preventable child deaths documented by UN human rights mandate holders [1, 3].

3. Clinical Fallout Across Vulnerable Patient Groups

Peer-reviewed studies in The Lancet (Danaei et al., 2019; Aloosh et al., 2019; Takian et al., 2020), Globalization and Health (Setayesh & Mackey, 2016), and the International Journal of Health Policy and Management (Kokabisaghi, 2018) document systemic clinical disruptions across major disease categories [4, 5, 6, 7, 8]:

| Patient Group | Estimated Affected Population in Iran | Sanctions & Overcompliance Bottleneck | Documented Clinical Impact |

| :--- | :--- | :--- | :--- |

| Thalassemia (Beta-Thalassemia Major) | ~23,000 patients | Blocked payments and shipments of iron-chelating therapies (Desferal / deferoxamine from European manufacturer Novartis and raw APIs from France's Roquette Frères). | Toxic iron accumulation in cardiac and hepatic tissue, organ failure, and documented spikes in preventable youth mortality [1, 3]. |

| Pediatric Oncology & Leukemia | Tens of thousands of active cases | Supply interruptions and 300–500% price surges for imported chemotherapy drugs (e.g., Asparaginase, Mercaptopurine) and diagnostic radiopharmaceuticals (documented at Mahak Children's Hospital). | Delayed treatment cycles, forced substitution with less effective regimens, and reduced pediatric survival rates [2, 6]. |

| Drug-Resistant Epilepsy | Tens of thousands of patients | Disappearance of foreign-manufactured anti-seizure medications from hospital and community pharmacies due to banking blockades. | Uncontrolled tonic-clonic seizures, physical trauma, and risk of permanent neurological damage in children and adults [2]. |

| Hemophilia & Multiple Sclerosis (MS) | ~12,000 hemophilia & >70,000 MS patients | Recurrent shortages of recombinant clotting factors (Factor VIII/IX) and MS disease-modifying therapies, coupled with catastrophic out-of-pocket costs. | Internal joint hemorrhages, irreversible arthropathy, and accelerated disability progression [1, 5, 6]. |


4. Macroeconomic Transmission: Inflation, Household Welfare & the Erosion of Civil Society

Economic sanctions do not operate solely on hospital supply chains; they restructure the socioeconomic fabric of society. Econometric analyses of Iran's national Household Expenditure and Income Survey (HEIS) microdata by Djavad Salehi-Isfahani (2023, Middle East Development Journal) and macroeconomic studies by Esfandyar Batmanghelidj (2022, Johns Hopkins SAIS) establish three key findings [9, 10]:

  1. Plummeting Real Wages Behind Nominal Employment: When oil and financial sanctions restrict foreign exchange reserves, the national currency undergoes severe devaluation. While currency depreciation preserved low-wage domestic import-substitution jobs, real wages and per-capita household consumption fell precipitously across a decade of economic stagnation [9].
  2. Regressive Impact on Vulnerable Demographics: Probit panel data modeling demonstrates that sanctions-induced inflation—dubbed "the inflation weapon"—disproportionately pushes urban households (who depend entirely on market purchases for food and rent), female-headed households, the elderly, and families lacking formal health insurance below the poverty line [9, 10].
  3. Hollowing Out the Middle Class and Civil Society: Sociological and economic evidence confirms that broad sanctions systematically erode the educated urban middle class. When household budgets are consumed entirely by food and medical survival, the social foundation for independent civil society, academic exchange, environmental NGOs, and cultural production is weakened, while opaque informal economies and sanctions-evasion networks expand [1, 9, 10].

5. International Humanitarian Law & Human Rights Assessment

Under international human rights treaties and customary international humanitarian law, comprehensive economic sanctions that impede civilian access to essential medicine and subsistence breach core legal obligations:

  • The Right to Health (ICESCR Article 12): Article 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR), interpreted through UN Committee on Economic, Social and Cultural Rights General Comment No. 14 (2000), explicitly states that States parties must refrain at all times from imposing embargoes or similar measures that restrict another country's supply of adequate medicines and medical equipment [1, 5].
  • The Right to Life (ICCPR Article 6) & Rights of the Child (CRC Article 24): Article 6 of the International Covenant on Civil and Political Rights (ICCPR) and Article 24 of the UN Convention on the Rights of the Child (CRC) guarantee every child's inherent right to life and the highest attainable standard of health. The UN Special Rapporteur (`A/HRC/51/33/Add.1`) concluded that preventable deaths resulting from blocked medical supplies (such as Mepilex dressings and thalassemia medications) constitute direct infringements of the right to life [1, 3].
  • Humanitarian Proportionality & Prohibition of Collective Punishment: Under international humanitarian principles, coercive measures whose foreseeable civilian harm vastly outweighs their stated political objectives violate the principle of proportionality and amount to collective punishment of a civilian population [1, 5].

6. Policy Recommendations for Finnish & Nordic Decision-Makers and Civil Society

Makan ry presents four concrete, evidence-based recommendations for Finnish foreign and security policy advisors, Members of Parliament, researchers, and civil society organizations:

  1. Nordic Regulatory & Financial Protection for Humanitarian Suppliers (*Safe Harbor* Mechanisms): Finland and its Nordic partners should advocate within the European Union for legally protected, state-backed humanitarian payment channels (via central banks or public development banks) so that Nordic medical manufacturers—such as Sweden's Mölnlycke Health Care or Finnish health-tech firms—can supply life-saving medical devices to civilian populations without facing secondary sanctions retaliation.
  2. Mandatory Human Rights Impact Assessments (HRIA) in EU Sanctions Policy: Within the EU Foreign Affairs Council, Finland should require that any renewal or expansion of sanctions regimes be preceded by an independent, empirical Human Rights Impact Assessment (HRIA) measuring impacts on medicine availability, pediatric mortality, and household poverty [1, 5].
  3. Operational Humanitarian Banking Corridors: Paper exemptions are meaningless when commercial banks refuse to clear payments. Finland and the EU must establish operational, de-risked banking corridors specifically dedicated to pharmaceuticals, Active Pharmaceutical Ingredients (APIs), and diagnostic hospital equipment [1, 2].
  4. Structured Finnish Civil Society & Medical Dialogue: We invite Finnish peace and humanitarian organizations (Suomen Sadankomitea, Suomen Rauhanliitto, Lääkärin sosiaalinen vastuu ry) and academic institutes (TAPRI, FIIA/UPI, Finnish universities) to partner with Makan ry in documenting the civilian impacts of sanctions and advancing human security (inhimillinen turvallisuus).

7. Primary References & Documentation

  1. United Nations Human Rights Council (2022). Report of the Special Rapporteur on the negative impact of unilateral coercive measures on the enjoyment of human rights, Alena Douhan, on her visit to the Islamic Republic of Iran. UN Doc. `A/HRC/51/33/Add.1` (17 August 2022).
  2. Human Rights Watch (2019). "Maximum Pressure": US Economic Sanctions Harm Iranians' Right to Health. New York: Human Rights Watch, October 29, 2019 (47 pp.).
  3. United Nations Office of the High Commissioner for Human Rights — OHCHR (2021–2024). Iran: Over-compliance with unilateral sanctions hurting rare disease and thalassemia patients, UN experts warn (Special Procedures communications and press releases documenting Mölnlycke Health Care / Mepilex wound dressing cutoffs and thalassemia medicine shortages).
  4. Setayesh, S., & Mackey, T. K. (2016). Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: promoting access to medicines and health diplomacy. Globalization and Health, 12(1), 31.
  5. Kokabisaghi, F. (2018). Assessment of the Effects of Economic Sanctions on Iranians' Right to Health by Using Human Rights Impact Assessment Tool: A Systematic Review. International Journal of Health Policy and Management (IJHPM), 7(5), 374–393.
  6. Danaei, G., Harirchi, I., Sajadi, H. S., Yahyaei, F., & Majdzadeh, R. (2019). The harsh effects of sanctions on Iranian health. The Lancet, 394(10197), 468–469.
  7. Aloosh, M., Salavati, A., & Aloosh, A. (2019). Economic sanctions threaten population health: the case of Iran. The Lancet Public Health, 4(2), e62.
  8. Takian, A., Raoofi, A., & Kazempour-Ardebili, S. (2020). COVID-19 battle during the toughest sanctions against Iran. The Lancet, 395(10229), 1035–1036.
  9. Salehi-Isfahani, D. (2023). The impact of sanctions on household welfare and employment in Iran. Middle East Development Journal, 15(2), 195–222.
  10. Batmanghelidj, E. (2022). The Inflation Weapon: How American Sanctions Harm Iranian Households. Washington, D.C.: Johns Hopkins SAIS & Sanctions and Security Research Project.